Drug Repurposing of Quisinostat to Discover Novel Plasmodium falciparum HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety

Author:

Wang Manjiong1,Tang Tongke23,Li Ruoxi1,Huang Zhenghui2,Ling Dazheng1,Zheng Lulu1,Ding Yan4,Liu Taiping4,Xu Wenyue4,Zhu Feng5,Min Hui5,Boonhok Rachasak5,Mao Fei1ORCID,Zhu Jin1ORCID,Li Xiaokang1,Jiang Lubin23,Li Jian167ORCID

Affiliation:

1. State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

2. Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China

3. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, P.R. China

4. Department of Pathogenic Biology, Army Medical University, Chongqing 400038, China

5. Division of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States

6. College of Pharmacy and Chemistry, Dali University, 5 Xue Ren Road, Dali 671000, China

7. Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China

Funder

Ministry of Science and Technology of the People's Republic of China

State Key Laboratory of Bioreactor Engineering

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

National Science and Technology Major Project

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism

Innovative Research Team of High-level Local Universities in Shanghai

Pu'er Municipal Expert Workstation of L. J.

Shanghai Morning Light Program

Key Collaborative Research Program of the Alliance of International Science Organizations

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3